Related Experiment Video
Updated: Jul 24, 2025

Methyl-binding DNA capture Sequencing for Patient Tissues
Published on: October 31, 2016
Ribosomal S6 kinase 4 (RSK4) tumor suppressor gene promoter methylation status in ovarian cancer
Fabian Arechavaleta-Velasco1, Pablo Dominguez-Lopez1, Ernesto Acosta-Jimenez1,2
1Unidad de Investigación Médica en Medicina Reproductiva, UMAE Hospital de Gineco-Obstetricia No. 4 "Luis Castelazo Ayala", Instituto Mexicano del Seguro Social, Av. Rio Magdalena No. 289, Sexto piso. Tizapán, San Angel, CP 01090, Mexico City, Mexico.
Background:
Previously, we reported lower RSK4 mRNA and protein levels in malignant ovarian tumors compared to normal and benign ovarian tissues. Also, we observed a significant inverse correlation between the advanced ovarian cancer stages and RSK4 mRNA levels. We did not investigate the mechanisms involved in RSK4-reduced expression in ovarian cancer. Thus, this study investigates whether RSK4 promoter methylation in ovarian cancer tissues is responsible for its low expression. Additionally, the reactivation of RSK4 expression and its effect was studied in ovarian cancer cell lines.
Methods And Results:
RSK4 promoter methylation percentage in malignant and benign ovarian tumors and normal ovary tissues was determined by combined bisulfite restriction analysis. The reactivation of RSK4 expression by decitabine treatment was studied in OVCAR3, SKOV3, TOV-112D, and TOV-21G cells by Western blotting. Cell proliferation was determined by XTT. A significantly high methylation percentage of the RSK4 promoter was observed among malignant and benign ovarian tumors but not in normal ovarian tissue. RSK4 promoter methylation was not associated with age, histological subtype, or stages of ovarian cancer. RSK4 promoter methylation correlates weakly but not significantly with RSK4 protein expression. No correlation was shown between RSK4 methylation and RSK4 mRNA expression. Decitabine induces RSK4 reactivation in all cell lines. However, cell proliferation was reduced only in TOV-112D cells.
Conclusion:
These data indicate that although RSK4 promoter methylation is increased in malignant ovarian tumors, this mechanism is unlikely to regulate its expression in ovarian cancer. RSK4 reactivation reduced cell proliferation only in the endometroid histological subtype.
Insights
Ovarian tumors show increased RSK4 promoter methylation, but it doesn't fully explain low RSK4 expression. Reactivating RSK4 expression reduced proliferation in specific ovarian cancer subtypes.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Reduced RSK4 mRNA and protein levels are observed in malignant ovarian tumors.
- A significant inverse correlation exists between advanced ovarian cancer stages and RSK4 mRNA levels.
- The mechanisms driving RSK4 downregulation in ovarian cancer remain unclear.
Purpose of the Study:
- To investigate if RSK4 promoter methylation causes reduced RSK4 expression in ovarian cancer.
- To explore RSK4 expression reactivation and its effects in ovarian cancer cell lines.
Main Methods:
- Combined bisulfite restriction analysis to assess RSK4 promoter methylation.
- Decitabine treatment to induce RSK4 reactivation in ovarian cancer cell lines (OVCAR3, SKOV3, TOV-112D, TOV-21G).
- Western blotting for RSK4 expression, and XTT assay for cell proliferation.
Main Results:
- Significantly higher RSK4 promoter methylation was found in malignant and benign ovarian tumors compared to normal tissue.
- RSK4 promoter methylation did not correlate with age, histological subtype, or cancer stage.
- Decitabine treatment reactivated RSK4 expression in all tested cell lines, but reduced proliferation only in TOV-112D cells.
Conclusions:
- RSK4 promoter methylation is increased in ovarian tumors but is unlikely the primary regulator of RSK4 expression in ovarian cancer.
- RSK4 reactivation demonstrated a selective inhibitory effect on cell proliferation, particularly in the endometrioid histological subtype.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Epigenetic Regulation
X-chromosome...
MicroRNAs
PI3K/mTOR/AKT Signaling Pathway
The Nucleolus

